课件：大肠癌化疗方案.ppt

* * * * * XELOX achieved a high response rate of 55%, with an additional 32% of patients having stable disease for at least 3?months [1]. The response rate, median progression-free survival (7.7 months) and median overall survival (19.5 months) with XELOX compare favourably with the results from a randomized study of infused 5-FU/LV with or without oxaliplatin (FOLFOX4), which demonstrated significant improvements for the combination compared with 5?FU/LV alone [2,3]. These data provide a high level of confidence that XELOX will be at least as effective as FOLFOX4 in a randomised comparison. ? ? 1. Sawada N et al. Eur J Cancer 2003;1(Suppl. 5):S93 (Abst 303). 2. Goldberg R et al. Proc Am Soc Clin Oncol 2003;22:252 (Abst 1009). 3. de Gramont A et al. J Clin Oncol 2000;18:2938–47. * The response rate (42%) and median TTP (7.1 months) achieved with XELIRI [1] compare favourably with the results from randomised trials evaluating either infused or bolus 5-FU in combination with irinotecan as first-line therapy for metastatic CRC [2–4]. ? 1. Patt YZ et al. Eur J Cancer 2003;1(Suppl. 5):S93 (Abst 304). 2. Goldberg RM et al. Proc Am Soc Clin Oncol 2003;22:252 (Abst 1009). 3. Saltz LB et al. N Engl J Med 2000;343:905–14. 4. Douillard JY et al. Lancet 2000;355:1041–7. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 小 结 FOLFOX和FOLFIRI方案成为转移性结直肠癌一线治疗的标准方案。整个过程使用3种药物（FU/OXO/CPT-11）使患者生存期达到20个月以上，如加上分子靶向药物治疗生存期延长到25个月左右。 XELIRI 和XELOX方案也可作为转移性结直肠癌的一线治疗方案。 小 结 单独使用分子靶向药物治疗效果不明显，但和原来的化疗药物应用，可以逆转耐药，延长生存期，改善生活质量，而且不增加毒性。 由于治疗的进步使晚期结直肠癌的生存期大大延长，这也改变了我们的观念，结直肠是一种慢性疾病而非急性致命性疾病。 THANK YOU * * * * * * * * * * * * * * * * * * * 3 开普托 180 mg/m2 IV + 简化 LV5FU 奥沙利铂 100 mg/m2 IV + 简化LV5FU * * * * * * * Two international, open-label, randomised, phase III trials have compared oral Xeloda with i.v. bolus 5-FU/LV (Mayo Clinic regimen). One trial was conducted in the Americas [1] and the other was performed in Europe, the Middle East and Australasia [2]. The